TY - JOUR
T1 - Failure Mode and Effects Analysis (FMEA) at the preanalytical phase for POCT blood gas analysis: proposal for a shared proactive risk analysis model.
AU - Bench, Suzanne
PY - 2022/5/24
Y1 - 2022/5/24
N2 - Objectives
Proposal of a risk analysis model to diminish negative impact on patient care by preanalytical errors in blood gas analysis (BGA).
Methods
Here we designed a Failure Mode and Effects Analysis (FMEA) risk assessment template for BGA, based on literature references and expertise of an international team of laboratory and clinical health care professionals.
Results
The FMEA identifies pre-analytical process steps, errors that may occur whilst performing BGA (potential failure mode), possible consequences (potential failure effect) and preventive/corrective actions (current controls). Probability of failure occurrence (OCC), severity of failure (SEV) and probability of failure detection (DET) are scored per potential failure mode. OCC and DET depend on test setting and patient population e.g., they differ in primary community health centres as compared to secondary community hospitals and third line university or specialized hospitals. OCC and DET also differ between stand-alone and networked instruments, manual and automated patient identification, and whether results are automatically transmitted to the patient’s electronic health record. The risk priority number (RPN = SEV × OCC × DET) can be applied to determine the sequence in which risks are addressed. RPN can be recalculated after implementing changes to decrease OCC and/or increase DET. Key performance indicators are also proposed to evaluate changes.
Conclusions
This FMEA model will help health care professionals manage and minimize the risk of preanalytical errors in BGA.
AB - Objectives
Proposal of a risk analysis model to diminish negative impact on patient care by preanalytical errors in blood gas analysis (BGA).
Methods
Here we designed a Failure Mode and Effects Analysis (FMEA) risk assessment template for BGA, based on literature references and expertise of an international team of laboratory and clinical health care professionals.
Results
The FMEA identifies pre-analytical process steps, errors that may occur whilst performing BGA (potential failure mode), possible consequences (potential failure effect) and preventive/corrective actions (current controls). Probability of failure occurrence (OCC), severity of failure (SEV) and probability of failure detection (DET) are scored per potential failure mode. OCC and DET depend on test setting and patient population e.g., they differ in primary community health centres as compared to secondary community hospitals and third line university or specialized hospitals. OCC and DET also differ between stand-alone and networked instruments, manual and automated patient identification, and whether results are automatically transmitted to the patient’s electronic health record. The risk priority number (RPN = SEV × OCC × DET) can be applied to determine the sequence in which risks are addressed. RPN can be recalculated after implementing changes to decrease OCC and/or increase DET. Key performance indicators are also proposed to evaluate changes.
Conclusions
This FMEA model will help health care professionals manage and minimize the risk of preanalytical errors in BGA.
U2 - 10.1515/cclm-2022-0319
DO - 10.1515/cclm-2022-0319
M3 - Article
SN - 1437-4331
VL - 60
SP - 1186
EP - 1201
JO - Clinical Chemistry and Laboratory Medicine (CCLM)
JF - Clinical Chemistry and Laboratory Medicine (CCLM)
IS - 8
ER -